0
Commentary |

Melanoma: Do We Need a Hatchet or a Scalpel?

Mark J. Shackleton, PhD; Elsa Quintana, PhD; Douglas R. Fullen, MD; Michael S. Sabel, MD; Timothy M. Johnson, MD
Arch Dermatol. 2009;145(3):307-308. doi:10.1001/archdermatol.2009.3.
Text Size: A A A
Published online

Extract

What proportion of cells in a malignant neoplasm have the potential to proliferate extensively: all cells, most of them, or only a small minority? This fundamentally important question has direct implications for clinical practice. Which cancer cells need to be killed to cure patients? It is critical both for cancer biologists and for investigators who are seeking to develop new treatments for cancer to know exactly which cells drive cancer growth.

Traditionally, it has been thought that more or less all cells in a malignant neoplasm have a similar potential to proliferate, propagating the disease in a stochastic (random) manner (Figure, A). This theory led to the development of “hatchet” treatments, ie, surgery, radiation therapy, and cytotoxic agents, that sought to eliminate every cell in a malignant neoplasm. Such treatments are of course effective if they eliminate every cancer cell, albeit at the cost of collateral damage to normal tissues. However, when cancers evade early detection or spread early in their development, the hope of killing every cell with a hatchet approach diminishes. This problem is compounded in cancers such as melanoma that are notoriously resistant to conventional systemic therapies.

Figures in this Article

Topics

melanoma

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
/>
First page PDF preview

Figures

Place holder to copy figure label and caption
Figure

Models of cancer growth (adapted by permission from Macmillan Publishers Ltd1). A, The traditional (stochastic) model in which most cancer cells can proliferate despite being phenotypically heterogeneous (colored cells), driving tumor growth in a stochastic manner. B, The cancer stem cell (CSC) model in which only a fraction of cells—the CSCs—proliferate, producing more CSCs as well as cells that undergo further genetic and epigenetic changes and do not proliferate extensively (called nontumorigenic cells [cells without circular arrows]). Important to the CSC model is the idea that CSCs are phenotypically distinct from nontumorigenic cells (colored cells), enabling their identification and specific targeting.

Graphic Jump Location

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Jobs
JAMAevidence.com

Users' Guides to the Medical Literature
Melanoma

The Rational Clinical Examination
Make the Diagnosis: Melanoma

brightcove.createExperiences();